

APPENDIX 3Ys – RICHARD JAGGER AND PETER MAY

The attached Appendix 3Y notices relate to dealings in Bio-Gene shares by Executive Directors, Richard Jagger and Peter May.

The following information should be considered:

- On 1 November 2019, Richard Jagger was issued 316,927 Bio-Gene shares and Peter May was issued 99,776 Bio-Gene shares, in respect to their Short Term Incentive (STI) for the 2019 financial year. These shares vested on issue and triggered an unfunded income tax obligation for both Executive Directors
- On 12 December 2019, Richard Jagger sold 148,955 shares and Peter May sold 46,895, representing 47 per cent of the STI shares issued to fund their tax obligations. The shares were sold for \$0.2698 each, resulting in \$39,969 in share sale proceeds for Richard Jagger, and \$12,583 in share sale proceeds for Peter May
- The sale was conducted with board approval and at the first opportunity following their issue within the designated share trading window for Company executives
- Richard Jagger and Peter May have no plans to sell any further shares in Bio-Gene

This release was approved for release by Don Brumley, Chairman of the Bio-Gene Board of Directors.

For further information, please contact:

Bio-Gene Technology Limited:

Richard Jagger
Chief Executive Officer
P: 03 9068 1062
E: bgt.info@bio-gene.com.au

Roger McPherson
CFO and Company Secretary
P: 03 9068 1062
E: Ebgt.info@bio-gene.com.au

Investor Relations:

Davina Gunn
Henslow
P: 0400 896 809
E: dgunn@henslow.com

About Bio-Gene Technology Limited

Bio-Gene is an Australian ag-tech development company enabling the next generation of novel insecticides to address the global problems of insecticide resistance and toxicity. Its novel platform technology is based on a naturally occurring class of chemicals known as beta-triketones. Beta-triketone compounds have demonstrated insecticidal activity (e.g. kill or knock down insects) via a novel mode of action in testing performed to date. This platform may provide multiple potential new solutions for insecticide manufacturers in applications across crop protection and food storage, public health, consumer applications and animal health. The Company's aim is to develop and commercialise a broad portfolio of targeted insect control and management solutions.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity - Bio-Gene Technology Limited
ABN – 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Richard Jagger
Date of last notice	1 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Karen Buckingham Pty Ltd atf Karen Buckingham Family Trust. 65,000 ordinary shares The Director is a beneficiary of the Family Trust
Date of change	1 November 2019
No. of securities held prior to change	Direct: 4,001,221 ordinary shares Indirect: 65,000 ordinary shares
Class	Ordinary shares
Number acquired	N/A
Number disposed	148,955
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$39,969.69
No. of securities held after change	Direct: 3,852,266 ordinary shares Indirect: 65,000 ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Sale of 47% of 2019 Short term incentive shares issued on 1 November 2019 to cover income tax obligations

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	



Roger McPherson
 Company Secretary
 18 December 2019

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity - Bio-Gene Technology Limited
ABN – 32 071 735 950

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Peter May
Date of last notice	1 November 2019

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Peter Donald and Sondra May atf May Superannuation Fund. 331,000 ordinary shares The Director is a member of the Superannuation Fund
Date of change	12 December 2019
No. of securities held prior to change	Direct: 1,519,322 ordinary shares Indirect: 331,000 ordinary shares
Class	Ordinary shares
Number acquired	N/A
Number disposed	46,895
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	\$12,583.52
No. of securities held after change	Direct: 1,472,427 ordinary shares Indirect: 331,000 ordinary shares
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Sale of 47% of 2019 Short term incentive shares issued on 1 November 2019 to cover income tax obligations

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Part 2 – Change of director's interests in contracts N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	



Roger McPherson
 Company Secretary
 18 December 2019

⁺ See chapter 19 for defined terms.